文献速递细菌感染、耐药与抗菌药物

12例扩大可及性定制噬菌体治疗的回顾性观察研究:生产、特征与临床结局

A Retrospective, Observational Study of 12 Cases of Expanded-Access Customized Phage Therapy: Production, Characteristics, and Clinical Outcomes.
PubMed 文献 · Clin Infect Dis · 2023-01-01

该回顾性观察研究评估了一个噬菌体生产中心12例定制噬菌体治疗耐抗菌药物感染患者的生产流程与结局。治疗后42%(5/12)病例实现细菌清除,58%(7/12)临床改善,三分之二病例(66%)获得有利应答,未观察到重大不良反应。

要点

  • 12例定制噬菌体治疗中42%(5/12)实现细菌清除,58%(7/12)临床改善,66%病例有利应答。
  • 未观察到重大不良反应,多数病例体外可见抗生素-噬菌体协同作用。
  • 5例报告噬菌体免疫中和,部分病例并发继发感染。

核心结论

  • 定制噬菌体生产与治疗是安全的,三分之二病例获得有利的临床或微生物学结局。
  • 作者认为,专门针对患者特定耐抗菌药物细菌感染定制噬菌体的中心或流程,在标准治疗失败时可能是可行选择。

研究设计与样本

  • 回顾性观察研究,来自一个噬菌体生产中心,共评估12例定制噬菌体治疗病例。
  • 噬菌体经筛选、纯化、测序、表征,并通过美国食品药品监督管理局(FDA)的IND(研究性新药)同情用药途径获批。
  • 结局按微生物学与临床标准判定为有利或不利;感染为器械相关或系统性。
  • 记录了治疗时间、抗生素协同及免疫反应等其他情况。

主要发现

  • 共收到50例噬菌体治疗请求,为12例患者生产了定制噬菌体。
  • 治疗后42%(5/12)病例显示细菌清除,58%(7/12)显示临床改善,全部病例中三分之二(66%)显示有利应答。
  • 未观察到重大不良反应。
  • 多数病例体外观察到抗生素-噬菌体协同作用。
  • 5例报告噬菌体免疫中和;部分病例并发继发感染。

关键数值与推荐

  • 细菌清除率42%(5/12),临床改善率58%(7/12),有利应答率66%。
  • 噬菌体免疫中和5例,重大不良反应未观察到。
  • 噬菌体形态学、基因组学与活性等完整表征及其生产方法、无菌与内毒素检测均有报告。

临床怎么用

  • 作者认为,专门针对患者特定耐抗菌药物细菌感染定制噬菌体的中心或流程,在标准治疗失败时可能是可行选择。
  • 噬菌体经FDA的IND同情用药途径获批使用,治疗前需完成筛选、纯化、测序与表征。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antimicrobial resistance (AMR) is undermining modern medicine, a problem compounded by bacterial adaptation to antibiotic pressures. Phages are viruses that infect bacteria. Their diversity and evolvability offer the prospect of their use as a therapeutic solution. Reported are outcomes of customized phage therapy for patients with difficult-to-treat antimicrobial resistant infections. METHODS: We retrospectively assessed 12 cases of customized phage therapy from a phage production center. Phages were screened, purified, sequenced, characterized, and Food and Drug Administration-approved via the IND (investigational new drug) compassionate-care route. Outcomes were assessed as favorable or unfavorable by microbiologic and clinical standards. Infections were device-related or systemic. Other experiences such as time to treatment, antibiotic synergy, and immune responses were recorded. RESULTS: Fifty requests for phage therapy were received. Customized phages were generated for 12 patients. After treatment, 42% (5/12) of cases showed bacterial eradication and 58% (7/12) showed clinical improvement, with two-thirds of all cases (66%) showing favorable responses. No major adverse reactions were observed. Antibiotic-phage synergy in vitro was observed in most cases. Immunological neutralization of phages was reported in 5 cases. Several cases were complicated by secondary infections. Complete characterization of the phages (morphology, genomics, and activity) and their production (methods, sterility, and endotoxin tests) are reported. CONCLUSIONS: Customized phage production and therapy was safe and yielded favorable clinical or microbiological outcomes in two-thirds of cases. A center or pipeline dedicated to tailoring the phages against a patient's specific AMR bacterial infection may be a viable option where standard treatment has failed.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Green SI, Clark JR, Santos HH, et al. A Retrospective, Observational Study of 12 Cases of Expanded-Access Customized Phage Therapy: Production, Characteristics, and Clinical Outcomes. Clin Infect Dis. 2023. PMID: 37279523. doi:10.1093/cid/ciad335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。